Literature DB >> 30012767

Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis.

Charles A Peloquin1, Patrick P J Phillips2,3, Carole D Mitnick4, Kathleen Eisenach5, Ramonde F Patientia6, Leonid Lecca7, Eduardo Gotuzzo8, Neel R Gandhi9,10,11, Donna Butler12, Andreas H Diacon6, Bruno Martel7, Juan Santillan8, Kathleen Robergeau Hunt12, Dante Vargas7, Florian von Groote-Bidlingmaier6, Carlos Seas8, Nancy Dianis12, Antonio Moreno-Martinez13,14, Pawandeep Kaur15, C Robert Horsburgh16,17.   

Abstract

Patients with multidrug-resistant tuberculosis in Peru and South Africa were randomized to a weight-banded nominal dose of 11, 14, 17, or 20 mg/kg/day levofloxacin (minimum, 750 mg) in combination with other second-line agents. A total of 101 patients were included in noncompartmental pharmacokinetic analyses. Respective median areas under the concentration-time curve from 0 to 24 h (AUC0-24) were 109.49, 97.86, 145.33, and 207.04 μg · h/ml. Median maximum plasma concentration (Cmax) were 11.90, 12.02, 14.86, and 19.17 μg/ml, respectively. Higher levofloxacin doses, up to 1,500 mg daily, resulted in higher exposures. (This study has been registered at ClinicalTrials.gov under identifier NCT01918397.).
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  antitubercular agents; levofloxacin; pharmacokinetics; tuberculosis

Mesh：

Substances：

Year:  2018        PMID： 30012767      PMCID： PMC6153781          DOI： 10.1128/AAC.00770-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

Review 1.  Pharmacokinetics and pharmacodynamics of antimicrobials.

Authors:  G L Drusano
Journal:  Clin Infect Dis       Date:  2007-07-15       Impact factor: 9.079

Review 2.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

3.  Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.

Authors:  Radha K Shandil; Ramesh Jayaram; Parvinder Kaur; Sheshagiri Gaonkar; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharath; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

4.  Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint.

Authors:  G L Drusano; S L Preston; C Hardalo; R Hare; C Banfield; D Andes; O Vesga; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

5.  In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

Authors:  B Ji; N Lounis; C Maslo; C Truffot-Pernot; P Bonnafous; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

6.  Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.

Authors:  Tawanda Gumbo; Arnold Louie; Mark R Deziel; Linda M Parsons; Max Salfinger; George L Drusano
Journal:  J Infect Dis       Date:  2004-09-24       Impact factor: 5.226

7.  Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.

Authors:  Charles A Peloquin; David Jamil Hadad; Lucilia Pereira Dutra Molino; Moises Palaci; W Henry Boom; Reynaldo Dietze; John L Johnson
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

8.  In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis.

Authors:  B JI; N Lounis; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

9.  Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system.

Authors:  G L Drusano; N Sgambati; A Eichas; D Brown; R Kulawy; A Louie
Journal:  MBio       Date:  2011-07-12       Impact factor: 7.867

10.  An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.

Authors:  Tara C Bouton; Patrick P J Phillips; Carole D Mitnick; Charles A Peloquin; Kathleen Eisenach; Ramonde F Patientia; Leonid Lecca; Eduardo Gotuzzo; Neel R Gandhi; Donna Butler; Andreas H Diacon; Bruno Martel; Juan Santillan; Kathleen Robergeau Hunt; Dante Vargas; Florian von Groote-Bidlingmaier; Carlos Seas; Nancy Dianis; Antonio Moreno-Martinez; C Robert Horsburgh
Journal:  Trials       Date:  2017-11-25       Impact factor: 2.279
View more
  6 in total

1.  Pharmacokinetics of Levofloxacin in Children Treated for Exposure to Drug-Resistant Tuberculosis.

Authors:  Hamidah Hussain; Courtney M Yuen; Amyn A Malik; Meredith B Brooks; Sara Siddiqui; Junaid Fuad; Charles A Peloquin; Farhana Amanullah; Maria Jaswal; Mercedes C Becerra
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

2.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors:  Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

3.  Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis.

Authors:  Samiksha Ghimire; Bhagwan Maharjan; Erwin M Jongedijk; Jos G W Kosterink; Gokarna R Ghimire; Daan J Touw; Tjip S van der Werf; Bhabana Shrestha; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

4.  Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania.

Authors:  Sagal Mohamed; Happiness C Mvungi; Margaretha Sariko; Prakruti Rao; Peter Mbelele; Erwin M Jongedijk; Claudia A J van Winkel; Daan J Touw; Suzanne Stroup; Jan-Willem C Alffenaar; Stellah Mpagama; Scott K Heysell
Journal:  J Antimicrob Chemother       Date:  2021-05-12       Impact factor: 5.790

5.  Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection.

Authors:  Mohammad H Al-Shaer; Wael A Alghamdi; Abdullah Alsultan; Guohua An; Shahriar Ahmed; Yosra Alkabab; Sayera Banu; Ketevan Barbakadze; Eric Houpt; Maia Kipiani; Lali Mikiashvili; J Peter Cegielski; Russell R Kempker; Scott K Heysell; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

6.  A mobile microvolume UV/visible light spectrophotometer for the measurement of levofloxacin in saliva.

Authors:  Jan-Willem C Alffenaar; Erwin M Jongedijk; Claudia A J van Winkel; Margaretha Sariko; Scott K Heysell; Stellah Mpagama; Daan J Touw
Journal:  J Antimicrob Chemother       Date:  2021-01-19       Impact factor: 5.790
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.